Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab with AVD in Newly Diagnosed Advanced Hodgkin's Lymphoma
NCT04843267Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- May 2021
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in Hodgkin lymphoma (HL), sponsored by Sun Yat-sen University. Primary endpoint: Complete Response Rate at 6 weeks. Status: unknown.
02
Drugs
tislelizumab
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT04843267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04843267.